Cargando…
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Autores principales: | Lentz, Steven R, Tandra, Anand, Gut, Robert Z, Cooper, David L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894958/ https://www.ncbi.nlm.nih.gov/pubmed/24470784 http://dx.doi.org/10.2147/JBM.S55216 |
Ejemplares similares
-
Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014) -
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study
por: Ma, Alice D., et al.
Publicado: (2016) -
A Case of Acquired Hemophilia A and Congenital Hemophilia B
por: Fortier, Julia C, et al.
Publicado: (2022) -
Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021) -
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)